Detalhe da pesquisa
1.
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Cell
; 172(3): 578-589.e17, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29373830
2.
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Nature
; 485(7397): 260-3, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22504184
3.
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
BMC Genomics
; 17: 455, 2016 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27296290
4.
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.
Bioorg Med Chem Lett
; 25(17): 3436-41, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26208887
5.
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Blood
; 114(14): 2984-92, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19654408
6.
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
Bioorg Med Chem Lett
; 19(17): 5182-5, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19646870
7.
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Clin Cancer Res
; 25(2): 796-807, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30327306
8.
Tuning a three-component reaction for trapping kinase substrate complexes.
J Am Chem Soc
; 130(51): 17568-74, 2008 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19053485
9.
A small molecule-kinase interaction map for clinical kinase inhibitors.
Nat Biotechnol
; 23(3): 329-36, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15711537
10.
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Cancer Res
; 66(2): 1007-14, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16424036
11.
An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors.
Sci Rep
; 8(1): 14312, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30254226
12.
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.
Nat Struct Mol Biol
; 25(6): 454-462, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29760531
13.
Comprehensive analysis of kinase inhibitor selectivity.
Nat Biotechnol
; 29(11): 1046-51, 2011 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22037378
14.
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Chem Biol
; 17(11): 1241-9, 2010 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21095574
15.
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
J Med Chem
; 52(23): 7808-16, 2009 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19754199
16.
High-throughput kinase profiling as a platform for drug discovery.
Nat Rev Drug Discov
; 7(5): 391-7, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18404149
17.
A quantitative analysis of kinase inhibitor selectivity.
Nat Biotechnol
; 26(1): 127-32, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18183025
18.
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proc Natl Acad Sci U S A
; 102(31): 11011-6, 2005 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-16046538